Publication details

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma

Authors	PALUMBO Antonio HÁJEK Roman DELFORGE Michel KROPFF Martin PETRUCCI Maria Teresa CATALANO John GISSLINGER Heinz WIKTOR-JEDRZEJCZAK Wieslaw ZODELAVA Mamia WEISEL Katja CASCAVILLA Nicola IOSAVA Genadi CAVO Michele KLOCZKO Janusz BLADE Joan BEKSAC Meral SPICKA Ivan PLESNER Torben RADKE Joergen LANGER Christian BEN Yehuda Dina CORSO Alessandro HERBEIN Lindsay YU Zhinuan MEI Jay JACQUES Christian DIMOPOULOS Meletios A.
Year of publication	2012
Type	Article in Periodical
Magazine / Source	New England Journal of Medicine
MU Faculty or unit	Faculty of Medicine
Citation
Field	Oncology and hematology
Keywords	PREDNISONE PLUS THALIDOMIDE; RANDOMIZED CONTROLLED-TRIAL; ELDERLY-PATIENTS; CELL TRANSPLANTATION; INITIAL TREATMENT; MELPHALAN; DEXAMETHASONE; CHEMOTHERAPY; MALIGNANCY; LEUKEMIA
Description	Background Lenalidomide has tumoricidal and immunomodulatory activity against multiple myeloma. This double-blind, multicenter, randomized study compared melphalan-prednisone-lenalidomide induction followed by lenalidomide maintenance (MPR-R) with melphalan-prednisone-lenalidomide (MPR) or melphalan-prednisone (MP) followed by placebo in patients 65 years of age or older with newly diagnosed multiple myeloma. Methods We randomly assigned patients who were ineligible for transplantation to receive MPR-R (nine 4-week cycles of MPR followed by lenalidomide maintenance therapy until a relapse or disease progression occurred [152 patients]) or to receive MPR (153 patients) or MP (154 patients) without maintenance therapy. The primary end point was progression-free survival. Results The median follow-up period was 30 months. The median progression-free survival was significantly longer with MPR-R (31 months) than with MPR (14 months; hazard ratio, 0.49; P<0.001) or MP (13 months; hazard ratio, 0.40; P<0.001). Response rates were superior with MPR-R and MPR (77% and 68%, respectively, vs. 50% with MP; P<0.001 and P=0.002, respectively, for the comparison with MP). The progression-free survival benefit associated with MPR-R was noted in patients 65 to 75 years of age but not in those older than 75 years of age (P=0.001 for treatment-by-age interaction). After induction therapy, a landmark analysis showed a 66% reduction in the rate of progression with MPR-R (hazard ratio for the comparison with MPR, 0.34; P<0.001) that was age-independent. During induction therapy, the most frequent adverse events were hematologic; grade 4 neutropenia was reported in 35%, 32%, and 8% of the patients in the MPR-R, MPR, and MP groups, respectively. The 3-year rate of second primary tumors was 7% with MPR-R, 7% with MPR, and 3% with MP. Conclusions MPR-R significantly prolonged progression-free survival in patients with newly diagnosed multiple myeloma who were ineligible for transplantation, with the greatest benefit observed in patients 65 to 75 years of age.